A Randomized trial comparing immediate versus delayed treatment of anemia with once-weekly epoetin alfa in patients with non-small cell lung cancer scheduled to receive first-line chemotherapy

被引:29
作者
Crawford, Jeffrey
Robert, Francisco
Perry, Michael C.
Belani, Chandra
Williams, Denise
机构
[1] Duke Univ, Med Ctr, Durham, NC 27710 USA
[2] Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL 35294 USA
[3] Univ Missouri, Columbia, MO USA
[4] Univ Pittsburgh, Pittsburgh, PA USA
[5] Johnson & Johnson Pharmaceut Res & Dev LLC, Raritan, NJ USA
关键词
epoetin alfa; chemotherapy-related anemia; non-small-cell lung cancer;
D O I
10.1097/JTO.0b013e318031cd9a
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: This study evaluated the safety/efficacy of once-weekly (QW) epoetin alfa measured by quality of life (QOL), hemoglobin (Hb), transfusion incidence, tumor response, and survival in patients with chemotherapy-naive, advanced non-small cell lung cancer (NSCLC). Methods: Stage IIIB/IV NSCLC patients with Hb >= 11 to <15 g/dl scheduled for at least 8 weeks of first-line chemotherapy were randomized to subcutaneously receive 40,000 U of epoetin alfa QW at chemotherapy initiation (immediate) or no epoetin alfa unless Hb decreased to <= 10 g/dl (delayed). The primary efficacy variable was change in QOL for immediate versus delayed intervention. Target accrual was 320 patients. Results: The study was terminated early because of slow accrual; of 216 patients enrolled, 211 were evaluable for efficacy. Hb was maintained in the immediate group, but it decreased in the delayed group (12.9 versus 11.6 g/dl final values, respectively). Numerically, fewer immediate patients required transfusions versus delayed patients. Mean QOL scores, modestly declining in both groups from baseline to final measurement, were not significantly different between groups. Tumor response and median overall survival were similar between groups. Epoetin alfa was well tolerated, with a similar thrombovascular event rate between groups. Conclusion: Epoetin alfa in subcutaneous doses of 40,000 U QW, given immediately at chemotherapy initiation for advanced NSCLC, was well tolerated, and it effectively maintained Hb, leading to a reduced transfusion incidence versus delayed epoetin alfa. Overall QOL scores were higher than typical in this population, decreasing slightly during treatment in both groups. Overall survival was similar between groups, with no evidence of a negative effect by early epoetin alfa intervention.
引用
收藏
页码:210 / 220
页数:11
相关论文
共 41 条
[1]  
*AMG INC, 2006, AR DARB ALF PRESCR I
[2]  
[Anonymous], 2002, ANN ONCOL
[3]   Erythropoietin or Darbepoetin for patients with cancer [J].
Bohlius, J. ;
Wilson, J. ;
Seidenfeld, J. ;
Piper, M. ;
Schwarzer, G. ;
Sandercock, J. ;
Trelle, S. ;
Weingart, O. ;
Bayliss, S. ;
Brunskill, S. ;
Djulbegovic, B. ;
Benett, C. L. ;
Langensiepen, S. ;
Hyde, C. ;
Engert, E. .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2006, (03)
[4]   Recombinant human erythropoietin and overall survival in cancer patients: Results of a comprehensive meta-analysis [J].
Bohlius, J ;
Langensiepen, S ;
Schwarzer, G ;
Seidenfeld, J ;
Piper, M ;
Bennett, C ;
Engert, A .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (07) :489-498
[5]   Recombinant human erythropoietins and cancer patients: Updated meta-analysis of 57 studies including 9353 patients [J].
Bohlius, Julia ;
Wilson, Jayne ;
Seidenfeld, Jerome ;
Piper, Margaret ;
Schwarzer, Guido ;
Sandercock, Josie ;
Trelle, Sven ;
Weingart, Olaf ;
Bayliss, Sue ;
Djulbegovic, Benjamin ;
Bennett, Charles L. ;
Langensiepen, Simon ;
Hyde, Chris ;
Engert, Andreas .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2006, 98 (10) :708-714
[6]   Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: Results of an eastern cooperative oncology group trial [J].
Bonomi, P ;
Kim, KM ;
Fairclough, D ;
Cella, D ;
Kugler, J ;
Rowinsky, E ;
Jiroutek, M ;
Johnson, D .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (03) :623-631
[7]  
BOWERS P, 2004, ONC DRUGS ADV COMM M
[8]  
Caro JJ, 2001, CANCER-AM CANCER SOC, V91, P2214, DOI 10.1002/1097-0142(20010615)91:12<2214::AID-CNCR1251>3.0.CO
[9]  
2-P
[10]   What is a clinically meaningful change on the Functional Assessment of Cancer Therapy-Lung (FACT-L) questionnaire? Results from Eastern Cooperative Oncology Group (ECOG) study 5592 [J].
Cella, D ;
Eton, DT ;
Fairclough, DL ;
Bonomi, P ;
Heyes, AE ;
Silberman, C ;
Wolf, MK ;
Johnson, DH .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 2002, 55 (03) :285-295